



Universiteit
Leiden
The Netherlands

Projected number of osteoarthritis patients in Austria for the next decades: quantifying the necessity of treatment and prevention strategies in Europe

Hitzl, W.; Stamm, T.; Kloppenburg, M.; Ritter, M.; Gaisberger, M.; Zee-neuen, A. van der

Citation

Hitzl, W., Stamm, T., Kloppenburg, M., Ritter, M., Gaisberger, M., & Zee-neuen, A. van der. (2022). Projected number of osteoarthritis patients in Austria for the next decades: quantifying the necessity of treatment and prevention strategies in Europe. *Bmc Musculoskeletal Disorders*, 23(1). doi:10.1186/s12891-022-05091-5

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3458825>

Note: To cite this publication please use the final published version (if applicable).

RESEARCH

Open Access



Projected number of osteoarthritis patients in Austria for the next decades – quantifying the necessity of treatment and prevention strategies in Europe

Wolfgang Hitzl^{1,2,3}, Tanja Stamm^{4,5}, Margreet Kloppenburg⁶, Markus Ritter^{7,8,9,10,11}, Martin Gaisberger^{7,9,10} and Antje van der Zee-Neuen^{7,10,12,13*}

Abstract

Background: The present study aimed to predict the expected number of patients with osteoarthritis (OA) in Austria up to the year 2080.

Methods: Demographic data and population projections between 2019 and 2080 were obtained from European authorities. Information about recent age- and sex-stratified prevalence of patients with self-reported physician-diagnosed OA was obtained from the Austrian Health Interview Survey ($n = 15,771$). Projections were stratified by age and sex; sensitivity analyses were performed based on aging, main (most likely), and growth scenarios of the population.

Results: Based on the projection, the overall increase in the total number of patients with OA from 2019 to 2080 will be 38% for men and women. In 2019, the highest number of OA-patients nested in the groups of persons aged 70-79 ($n = 238,749$) and 60-69 ($n = 237,729$) years. In 2080, the 80+ age group is predicted to have the highest number of OA with 421,548 individuals (i.e. factor 3.45 and factor 2.48 increase in the male and female group, respectively, compared to 2019), followed by the group aged 70-79 with 314,617 individuals (factor 1.45 and factor 1.28 increase in the male and female group, respectively, compared to 2019). Similar trends were found in the ageing and growing scenarios.

Conclusions: The projected increase in the occurrence of OA will likely lead to a substantial socioeconomic burden for the Austrian healthcare system in the near and far future. The current findings plead for the development of sustainable concepts for the treatment and prevention of OA by European authorities.

Keywords: Osteoarthritis, Epidemiology, Health economics, Pain assessment and management, Information science, Aging, Greying

Background

Osteoarthritis (OA) is among the most common musculoskeletal diseases in the world, causing pain, loss of function, disability and excess mortality [1, 2]. It can affect all joints, with the highest incidence in weight-bearing joints (i.e. knees and hips) [3]. It is a heterogeneous disorder including several phenotypes and research to establish a unified definition of OA is still ongoing

*Correspondence: antje.zee@pmu.ac.at

¹⁰ Gastein Research Institute, Paracelsus Medical University, Strubergasse

22, A-5020 Salzburg, Austria

Full list of author information is available at the end of the article



[4]. OA is known to adversely affect (work-)participation resulting in sick leave and work disability, impaired physical functioning in daily life, restrictions in caring for children and relatives, self-care activities, household chores and leisure activities [5, 6]. Hospitalizations due to OA in people aged 50+ already lead to a great impact on public health systems [7–11]. The costs for musculoskeletal disorders, with OA as the most common form, in countries like Australia, Canada, France, United Kingdom and the United States account for 1.0 to 2.5% of the gross domestic product [12, 13]. A Canadian study calculated the direct costs per person and year affected by OA to \$3,952 and the indirect costs to \$1,760 [14]. A study based on Dutch national data showed that 3-months healthcare costs were 2.3 times higher in persons with musculoskeletal disorders compared to those without. A larger increase in costs was only seen in persons reporting cancer [15].

Up to date, there is no cure for OA. The therapeutic options for OA encompass behavioural, non-pharmacological and/or pharmacological pain-alleviating and functionality improving or stabilizing symptomatic measures as well as surgical measures [2, 16, 17].

Among medications, non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequently used ones, many of them easily available over-the-counter. However, besides their superb effectiveness, NSAIDs have also a broad bandwidth of side effects, especially in patients with comorbidities. They cause gastrointestinal, renal, hepatic, cardiovascular, cerebral and pulmonary complications which not only pose additional harm to the patients but too frequently end up lethally. Around 30% of hospital admissions for cause adverse drug reactions (ADRs) are due to NSAIDs. Likewise, the use of opioid analgesics frequently causes ADRs. This also brings along high bed occupancy and huge costs that add on the socio-economic impact of OA per se [18–21]. These considerations have also to account for co-medications prescribed to prevent such ADRs, like e.g. anti-secretory drugs (proton pump inhibitors, H₂-blockers) to avoid gastrointestinal bleedings [22, 23]. These drugs, though eventually cost effective in a more holistic calculation, may cause ADRs themselves [24].

The increase in life expectancy in the populations of European countries, also known as the “population greying in Europe”, is a demographic phenomenon characterized by a decrease in fertility and an increase of life expectancy. It results in a higher proportion of older people in the (working) society [25]. The comparison of age pyramids for 2016 and 2080 (Fig. 1) shows a continuation of the aging of the EU population. In the coming decades, the number of elderly people will increase significantly. By 2080, the pyramid will develop into the shape of a

block, narrowing considerably in the middle of the pyramid (around the age 45–54 years).

In view of this population growth, the growing prevalence of OA with increasing age, its adverse association with work participation, a growing number of the elderly as part of the workforce and the costs related to healthcare consumption (associated with OA-specific complaints or ADRs), it seems plausible to assume that OA will have a growing impact on health care and social systems in Austria and in comparable countries.

Projection of the expected number of OA-patients in the future is a crucial step when planning and budgeting efforts for the treatment and prevention of OA. However, to our best knowledge, no reliable data is available for European countries estimating the number of patients with OAs in the near and distant future. Therefore, the aim of this study was to forecast the number of patients with OA in Austria from 2019 to 2080.

Methods


Analytic overview

We used publicly available demographic information and data from the Austrian Health Interview Survey (ATHIS) 2014 questionnaire that estimated the number of subjects with self-reported physician-diagnosed OA from the year 2019 [8]. The survey interviewed 15,771 randomly selected Austrian citizens (i.e. 0.22% of the total general population) aged 15 years or older about their health status and anonymized the data without the possibility of un-blinding. OA was counted if a person stated that this disease occurred within the last 12 months and that it was diagnosed by a physician. The survey only asked for the presence of OA, whereas arthritis (systemic inflammatory form) was explicitly not included in the questioning.

Demographic data sources

Demographic information on the number of Austrian inhabitants and population projections by decade between 2019 and 2080 was provided by Eurostat.

(<https://ec.europa.eu/eurostat/web/main/data/database>), the statistical office of the European Union. It provides statistics at the European level that enable comparisons between countries and regions. Specifically, it offers information from economic, demographic, social, ecologic and cultural sectors for the federal and regional authorities as well as for research, socio-economic, and public institutions. Datasets containing demographic information are publicly available and were downloaded from Eurostat (see database: “population and social conditions”, subsection: “population projections”). Data on the demographic development were stratified by age and sex and are given in decades.



Estimates of age and sex stratified prevalence of patients with self-reported physician-diagnosed OA

Information on age and sex-stratified OA prevalence in Austria among subjects aged ≥ 20 years (i.e. 12,78 per 100,000) was obtained from ATHIS 2014 [26] and applied to the year 2019.

Forecasting the expected number of subjects with OA

Lower and upper bounds for demographic development between 2019 and 2080 were used for three different population scenarios.

- **Ageing scenario:** lower fertility, shorter life expectancy, lower rate of immigration.
- **Main scenario:** most likely scenario; mean fertility, mean life expectancy, mean rate of immigration.

- **Growth scenario:** higher fertility, longer life expectancy, higher rate of immigration.

These scenarios are reflecting different assumptions on population growth and aging in Austria deduced from fertility, life expectancy, and immigration calculations which were derived from EUROSTAT scenarios (<http://ec.europa.eu/eurostat/data/database>, see database: “population and social conditions”, subsection: “population projections”).

“Lower fertility” was defined as 20% lower fertility rates than in the baseline assumptions, in each year of the entire horizon of projections. “Mean fertility” reflected that fertility remained constant over time. “Higher fertility” was defined as 20% higher fertility rates than in the baseline assumptions, in each year of the entire horizon of projections.

“Shorter life expectancy” assumed that the mortality rates are increased such that the life expectancy at birth will decrease by about two years by 2080 when compared with the baseline assumptions. “Longer life expectancy” assumed that the mortality rates are decreased such that the life expectancy at birth will increase by about two years by 2080 when compared with the baseline assumptions.

“Lower rate of immigration” was defined as 33% lower net migration than in the baseline assumptions, in each year of the entire horizon of projections. A “higher rate of immigration” reflected that the net migration was 33% higher than in the baseline assumptions, in each year of the entire horizon of projections.

The forecasts for OA total numbers were created under the assumption that the prevalence of OA would stay stable within each age and sex group during the investigated period. Based on the changing absolute number of people within each stratum, the number of patients with OA either increases or decreases. Computation was done by combining population projections provided by Eurostat with the assumption of stable prevalence over time. For example, in 2019, the prevalence of OA among women aged 70-75 was 41.025% (86,520/210,892). The absolute number of women in this age category is expected to increase to 278,189 by the year 2080, and thus we estimated the number of women with OA aged 70-75 to be 114,129 in 2080 (i.e. $278,189 \times 0.41025$). Predictions were carried out for the three different population scenarios and were stratified by age and sex. The age groups studied were: 20-29, 30-39, 40-49, 50-59, 60-69, 70-79 and 80+ years, respectively.

For the main-scenario, the sex-specific prevalence of OA was projected per 5-year increments (i.e. 2019-2080).

Results

In 2019, the total Austrian population aged 20+ years consisted of 7.16 million people (3.48 million men and 3.68 million women, respectively). Using the ageing scenario resulted in an estimated population of 8.1 million people in 2080, while using the growing scenario predicted a population of 9.97 million people.

Approximately 13% (12.78%, $n=914,652$) of the Austrian population reported physician-diagnosed OA in 2019 [8% (7.88%, $n=247,599$) of all men ≥ 20 years and 17% (17.41%, $n=640,054$) of all women]. A detailed overview of the age- and sex-stratified prevalence is provided in Fig. 2. The sex-specific prevalence of OA per 5-year increment for the main scenario is provided in Fig. 3.

All scenarios predicted considerably higher numbers of OA-patients in 2080. Table 1 shows the estimated percent change in the total number of subjects with self-reported physician-diagnosed OA from 2019 to 2080 for each of

the population growth scenarios (i.e. main scenario of population, growing scenario and ageing scenario).

Using the main scenario, the population of all subjects aged 20 years and older was estimated to increase to 8.08 million in the year 2080 (3.94 million men and 4.13 million women; i.e. +13% for both sexes). From 2019 to 2080 the corresponding number of subjects reporting physician-diagnosed osteoarthritis was estimated to increase by 38%. The total number of Austrian subjects reporting physician-diagnosed OA in the year 2019 was 12,775 per 100,000 individuals with more women than men affected (i.e. 640,054 women compared to 274,599 men in absolute numbers). The forecast predicted 15,570 per 100,000 individuals aged 20+ for the year 2080 (i.e. 876,426 women and 382,437 men). Of all subjects younger than 20 years of age 0.36% of had self-reported physician-diagnosed osteoarthritis (data not shown).


Aged-stratified estimations showed alterations in the age group most affected by OA: In 2019, the group with the highest numbers of OA patients was 70-79 years of age (238,749 individuals), followed by the 60-69 years group (237,729 individuals). For 2080, the forecast predicted that the age group 80+ will comprise the highest number of OA patients (421,548 individuals), followed by the 70-79 years group (314,617 individuals) (Fig. 2).

From 2019 to 2080, the number of OA patients in the age groups 60-69, 70-79 and 80+ were estimated to increase by factors 1.18, 1.45 and 3.45 in men and 1.13, 1.28 and 2.48 in women, respectively.

The projected number of subjects with self-reported physician-diagnosed OA in Austria from 2019 to 2080 for all age and sex strata is illustrated in Fig. 4.

Discussion

The results of the current study reveal that the total number of persons with OA in Austria will increase substantially until the year 2080. The overall predicted increase is 38% when comparing results for 2019 and 2080 in men and women. The largest increase is seen in the male groups aged 70-79 and 80+, which showed an increase of 45% and 245%, respectively. In comparison, women in these two age groups are estimated to contribute to the increase with 28% and 148%. This forecast is based on the estimated main scenario. A calculation of a growth scenario (i.e. high fertility, long life expectancy, and an additional high rate of immigration), results in an expected increase of 360% for men and 209% for women aged 80+ from 2019 to 2080. Considering the current immigration situation in Europe, the latter scenario seems most plausible. During the last decades life expectation in western countries rose constantly and the gap in average mortality age between men and women is getting smaller [27]. Considering enhanced medical treatment and stable



political systems, it is plausible to assume that by the year 2080 far more men will reach 80+ years. According to Eurostat, the European population aged 75+ years will increase between 160 and 476% (numbers from Italy and Luxemburg, respectively) depending on which European country. An age and sex stratified constant OA prevalence will therefore increase the total number of OA patients severely also due to the fact that the prevalence is highly age-dependent.

In accordance with our own findings, a Swedish population-based study projected an increase in OA

prevalence among adults aged 45 and older from 26.6% to 2012 to 29.5% in 2032 [28]. An Australian study predicted a steep increase in OA-prevalence as well showing an increase from 2.2 million OA patients in 2015 to almost 3.1 million in 2030. The study also stated that OA associated healthcare costs would increase from over \$2.1 billion in 2015 to more than \$2.9 billion in 2030 (\$970 for every OA-patient) [29]. This increase in prevalence and costs over a relatively short period of time points towards the relevant impact the increase may have on healthcare systems when considering a longer period of time.




Fig. 3 Sex-stratified projected number of self-reported physician-diagnosed osteoarthritis in Austria from 2019 to 2080 per 5 year increment sex (main scenario). Source-data derived from the Austrian Health Interview Survey

Table 1 Estimated change (%) of subjects with self-reported physician-diagnosed osteoarthritis from 2019 to 2080 in Austria. Estimates are based on the main scenario of population growth (M), growing scenario (G) and ageing scenario (A)

Year	Age																				
	20-29			30-39			40-49			50-59			60-69			70-79			80+		
	M	A	G	M	A	G	M	A	G	M	A	G	M	A	G	M	A	G	M	A	G
	Men																				
2019	100 ¹	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
2020	99	99	99	101	101	101	99	99	99	101	101	101	103	103	103	98	102	98	109	109	109
2030	89	83	95	98	93	104	104	100	107	85	83	87	132	131	134	117	118	119	146	152	153
2040	91	84	99	91	81	102	102	94	111	89	84	94	113	111	119	152	155	159	193	209	212
2050	92	80	105	94	82	105	96	84	109	88	80	98	120	114	130	135	135	146	271	304	312
2060	91	72	111	94	79	110	98	84	112	84	72	96	120	109	135	146	143	163	280	321	343
2070	92	68	118	93	73	114	98	82	119	85	73	98	115	100	134	148	139	173	311	351	396
2080	93	66	125	94	71	119	98	77	119	86	71	102	118	102	138	145	130	174	345	378	460
	Women																				
2019	100 ¹	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
2020	99	99	99	101	101	101	98	98	98	101	101	101	103	103	103	98	98	98	106	106	106
2030	90	83	96	99	94	103	100	98	103	87	86	88	128	128	130	112	112	113	130	134	134
2040	91	83	100	93	83	102	100	93	106	90	87	94	111	109	115	141	142	145	162	171	173
2050	93	81	106	94	84	105	93	82	104	89	82	96	117	112	123	125	124	131	214	231	237
2060	92	73	112	95	80	110	94	82	107	85	74	96	115	106	127	132	129	143	217	239	252
2070	93	70	118	94	75	115	95	81	111	86	75	98	110	97	126	132	123	147	232	253	277
2080	94	67	125	95	72	120	95	75	115	87	73	102	113	98	129	128	114	148	248	264	309

65% 100% (= year 2019) 460%

Colour-shading based on 5-percent decrease and increment from 2019; ¹100% corresponds to 2019 in each group (M, G, A).




Fig. 4 Estimated prevalence of self-reported physician-diagnosed osteoarthritis in Austria for men in women in all age-groups based on 2019 prevalence estimates from the Austrian Health Interview Survey (ATHIS)

Limitations and considerations

The present study is based on demographic estimates for the period from 2019 to 2080 in the Austrian population. Naturally, factors such as migration, population growth, and aging deduced from fertility, life expectancy, and immigration calculations may vary considerably until 2080. To account for these factors, we provided three different scenarios, i.e. an aging, main (most likely) and growth scenario, respectively. Socio-economic changes of the population, war, and natural disasters were assumed to remain unaltered during the projection period. Though this approach has restrictions, it nevertheless allows for the application of the forecast model in the calculation of age-adjusted predictions of OA total numbers in other western countries if adjusted to the respective population growth scenarios. The current analyses are exclusively reflections of the demographic changes of the Austrian population. Changes in actual OA prevalence rates were not assumed due to the complex nature of potential factors influencing the actual increase or decrease of the occurrence of OA. Changes in environmental influences on the population like increase in health literacy, increase in mobility/migration, natural disasters or war were not taken into account. On the one hand, changes in environmental influences on the population, smart homes, work behaviour and assistive technologies may increase OA prevalence due to an increase in body mass index (BMI) [30, 31]. On the other hand, improved prevention, increased health literacy, more physical activity and better medical treatment may decrease the prevalence

[32–34]. However, research regarding these preventive measures is still extremely limited. Therefore, future effects of these factors on OA prevalence cannot be reliably estimated at the moment. Age and BMI adjusted comparisons between early and post-industrial samples show at least a 2.1 times higher prevalence of knee OA in the United States of America [35]. This indicates that there are more, yet not entirely explored risk factors playing a role in the prevalence of OA. A more precise estimation of joints affected by OA could be useful when designing preventive strategies. Therefore, future health surveys should ideally discriminate OA in subgroups like knee, hip, spine and hand. Epidemiologic studies show that the prevalence of OA in the western world is around 14.8% ($n=4733$; age ≥ 18 years) [36]. Estimates of the American Bone and Joint Initiatives show that almost 23% of the US population report a physician diagnosed form of arthritis with OA representing the largest part of this group [37]. Our number of self-reported physician diagnosed OA is in good accordance with these numbers and indicates that the data is reliable. While diagnosis by health professionals is certainly most reliable, previous research showed that asking respondents specifically for physician-confirmed diagnosis is beneficial in increasing the accuracy of self-reported disease [38].

Conclusions

The increase in osteoarthritis patients predicted by the current study emphasizes the necessity of developing, implementing and financing sustainable interventions for

the treatment but - more importantly - the prevention of osteoarthritis. Authority-driven public health campaigns might use these numbers to inform community policy makers and general populations and to initiate lifestyle changes promoting healthy behaviour aiming to reduce the incidence of OA.

Abbreviations

ATHIS: Austrian Health Interview Survey; BMI: body mass index; EU: European Union; OA: osteoarthritis.

Acknowledgements

N/A.

Authors' contributions

WH, MR & MG conceptualized the study, WH analysed the data and wrote the initial draft of the manuscript in collaboration with WH, MR, MG & MK. AZ reviewed the concept, manuscript and analyses and altered the manuscript accordingly. All authors reviewed the final version of the manuscript and agreed to submission in its current form.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Projection data were obtained via the European Commission database Eurostat <http://ec.europa.eu/eurostat/data/database>. ATHIS data was obtained via Statistics Austria: http://www.statistik.at/web_de/services/mikrodaten_fuer_forschung_und_lehre/datenangebot/standardisierte_datensatze_sds/index.html.

Declarations

Ethics approval and consent to participate

Ethics approval and informed consent were not required since the current study exclusively comprises secondary analyses of de-identified data and data used in this study are freely available in the public domain for secondary use. The acquisition, provision and analyses of data in this study is in agreement with the European General Data Protection Regulation 2018. Analyses were performed in accordance with the Declaration of Helsinki.

Consent for publication

N/A.

Competing interests

The authors have no conflicts of interest to disclose.

Author details

¹Research and Innovation Management (RIM), Biostatistics, Paracelsus Medical University, Salzburg, Austria. ²Department of Ophthalmology and Optometry, Paracelsus Medical University, Salzburg, Austria. ³Research Program Experimental Ophthalmology and Glaucoma Research, Paracelsus Medical University, Salzburg, Austria. ⁴Section for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria. ⁵Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Medical University of Vienna, Vienna, Austria. ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands. ⁷Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology, Salzburg, Austria. ⁸Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology, Pathophysiology and Biophysics, Nuremberg, Germany. ⁹Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria. ¹⁰Gastein Research Institute, Paracelsus Medical University, Strubergasse 22, A-5020 Salzburg, Austria. ¹¹Kathmandu University School of Medical Sciences, Dhulikhel, Nepal. ¹²Institute of Nursing

Science and Practice, Paracelsus Medical University, Salzburg, Austria. ¹³Centre for Public Health and Health Services Research, Paracelsus Medical University, Salzburg, Austria.

Received: 12 November 2021 Accepted: 3 February 2022

Published online: 09 February 2022

References

- Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. *BMJ*. 2011;342:d1165.
- Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet*. 2019;393(10182):1745–59.
- Zhang Y, Jordan JM. Epidemiology of osteoarthritis. *Clin Geriatr Med*. 2010;26(3):355–69.
- Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. *Osteoarthritis Cartilage*. 2015;23(8):1233–41.
- Bieleman HJ, Bierma-Zeinstra SM, Oosterveld FG, Reneman MF, Verhagen AP, Groothoff JW. The effect of osteoarthritis of the hip or knee on work participation. *J Rheumatol*. 2011;38(9):1835–43.
- Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. *Radiol Clin North Am*. 2004;42(1):1–9, v.
- Arden N, Nevitt MC. Osteoarthritis: epidemiology. *Best Pract Res Clin Rheumatol*. 2006;20(1):3–25.
- Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage*. 2008;16(2):137–62.
- Wang TJ, Belza B, Elaine Thompson F, Whitney JD, Bennett K. Effects of aquatic exercise on flexibility, strength and aerobic fitness in adults with osteoarthritis of the hip or knee. *J Adv Nurs*. 2007;57(2):141–52.
- Laires PA, Canhão H, Rodrigues AM, Eusébio M, Gouveia M, Branco JC. The impact of osteoarthritis on early exit from work: results from a population-based study. *BMC Public Health*. 2018;18(1):472.
- Lo J, Chan L, Flynn S. A Systematic Review of the Incidence, Prevalence, Costs, and Activity and Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 Update. *Arch Phys Med Rehabil*. 2021;102(1):115–31.
- Bitton R. The economic burden of osteoarthritis. *Am J Manag Care*. 2009;15(8 Suppl):S230–5.
- March LM, Bachmeier CJ. Economics of osteoarthritis: a global perspective. *Baillieres Clin Rheumatol*. 1997;11(4):817–34.
- Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C, Team CHaAPS. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. *Ann Rheum Dis*. 2004;63(4):395–401.
- van der Zee-Neuen A, Putrik P, Ramiro S, Keszei A, de Bie R, Chorus A, et al. Impact of Chronic Diseases and Multimorbidity on Health and Health Care Costs: The Additional Role of Musculoskeletal Disorders. *Arthritis Care Res (Hoboken)*. 2016;68(12):1823–31.
- Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P, Conaghan PG, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. *Ann Rheum Dis*. 2013;72(7):1125–35.
- Carbone LD, Satterfield S, Liu C, Kwok KC, Neogi T, Tolley E, et al. Assistive walking device use and knee osteoarthritis: results from the Health, Aging and Body Composition Study (Health ABC Study). *Arch Phys Med Rehabil*. 2013;94(2):332–9.
- Davis A, Robson J. The dangers of NSAIDs: look both ways. *Br J General Pract*. 2016;66(645):172–3. <https://doi.org/10.3399/bjgp16X684433>.
- Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *Bmj*. 2004;329(7456):15–9.
- Courtney P, Doherty M. Key questions concerning paracetamol and NSAIDs for osteoarthritis. *Ann Rheum Dis*. 2002;61(9):767–73.
- da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs

- and opioid treatment for knee and hip osteoarthritis: network meta-analysis. *BMJ*. 2021;375:n2321.
22. Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, et al. The appropriate use of proton-pump inhibitors. *Minerva Med*. 2018;109(5):386–99.
 23. Simoens S, De Coster S, De Ruyck B, Stutz P, Laekeman G. Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDs. *Pharm World Sci*. 2006;28(5):309–17.
 24. Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. *BMJ*. 2009;339:b2538.
 25. Carone G, Costello D. Can europe afford to grow old? Finance and Development. 2005:43–53.
 26. J. K. Österreichische Gesundheitsbefragung 2014. Hauptergebnisse des Austrian Health Interview Survey (ATHIS) und methodische Dokumentation. *Wien Statistik Austria*; 2015.
 27. Sundberg L, Agahi N, Fritzell J, Fors S. Why is the gender gap in life expectancy decreasing? The impact of age- and cause-specific mortality in Sweden 1997–2014. *Int J Public Health*. 2018;63(6):673–81.
 28. Turkiewicz A, Petersson IF, Björk J, Hawker G, Dahlberg LE, Lohmander LS, et al. Current and future impact of osteoarthritis on health care: a population-based study with projections to year 2032. *Osteoarthritis Cartilage*. 2014;22(11):1826–32.
 29. Ackerman IN, Pratt C, Gorelik A, Liew D. Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis. *Arthritis Care Res (Hoboken)*. 2018;70(6):877–83.
 30. Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. *J Bone Joint Surg Am*. 2012;94(3):201–7.
 31. Tukker A, Visscher TL, Picavet HS. Overweight and health problems of the lower extremities: osteoarthritis, pain and disability. *Public Health Nutr*. 2009;12(3):359–68.
 32. Whittaker JL, Runhaar J, Bierma-Zeinstra S, Roos EM. A lifespan approach to osteoarthritis prevention: Narrative review, part of the series "Foundations of OA" for OAC. *Osteoarthritis Cartilage*. 2021.
 33. Hohmann E. Editorial Commentary: More Clinical Trials Should Focus on Primary Prevention of Osteoarthritis: Disruptive Thinkers Are Required. *Arthroscopy*. 2021;37(8):2640–1.
 34. DePhillipo NN, Aman ZS, Dekker TJ, Moatshe G, Chahla J, LaPrade RF. Preventative and Disease-Modifying Investigations for Osteoarthritis Management Are Significantly Under-represented in the Clinical Trial Pipeline: A 2020 Review. *Arthroscopy*. 2021;37(8):2627–39.
 35. Wallace IJ, Worthington S, Felson DT, Jurmain RD, Wren KT, Maijanen H, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. *Proc Natl Acad Sci U S A*. 2017;114(35):9332–6.
 36. Plotnikoff R, Karunamuni N, Lytvyak E, Penfold C, Schopflocher D, Imayama I, et al. Osteoarthritis prevalence and modifiable factors: a population study. *BMC Public Health*. 2015;15:1195.
 37. Initiative USBaJ. The Burden of Musculoskeletal Diseases in the United States (BMUS) Rosemont, IL 2018 4.
 38. Haapanen N, Miilunpalo S, Pasanen M, Oja P, Vuori I. Agreement between questionnaire data and medical records of chronic diseases in middle-aged and elderly Finnish men and women. *Am J Epidemiol*. 1997;145(8):762–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

